1. Home
  2. PPG vs UTHR Comparison

PPG vs UTHR Comparison

Compare PPG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PPG Industries Inc.

PPG

PPG Industries Inc.

HOLD

Current Price

$119.86

Market Cap

27.9B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$539.56

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPG
UTHR
Founded
1883
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Paints/Coatings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.9B
25.1B
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
PPG
UTHR
Price
$119.86
$539.56
Analyst Decision
Buy
Buy
Analyst Count
12
14
Target Price
$124.25
$567.57
AVG Volume (30 Days)
1.5M
449.6K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
2.71%
N/A
EPS Growth
46.11
13.07
EPS
1.70
5.82
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$4.42
$6.39
Revenue Next Year
$3.03
$14.18
P/E Ratio
$69.88
$91.01
Revenue Growth
N/A
2.38
52 Week Low
$93.39
$272.18
52 Week High
$133.43
$609.35

Technical Indicators

Market Signals
Indicator
PPG
UTHR
Relative Strength Index (RSI) 54.23 47.44
Support Level $100.08 $533.78
Resistance Level $124.94 $542.66
Average True Range (ATR) 2.99 12.53
MACD -0.59 -1.13
Stochastic Oscillator 52.83 47.70

Price Performance

Historical Comparison
PPG
UTHR

About PPG PPG Industries Inc.

PPG is the world's second-largest producer of paints and coatings. PPG's products are sold to a wide variety of end users, including industrial segments such as automotive, aerospace, and protective and marine, as well as paint contractors and do-it-yourself customers. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: